Allergan to Showcase Novel and Expanding Eye Care Portfolio with New Data Presentations at the 2016 American Academy of Ophthalmology Annual Meeting in Chicago

DUBLIN, Oct. 10, 2016 /PRNewswire/ -- Allergan (NYSE: AGN) today announced that its data will be presented during the 2016 American Academy of Ophthalmology (AAO) Annual Meeting in Chicago, October 14-18.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

The scheduled times (noted in local Central Time) of the four presentations and locations at McCormick Place are as follows:

Retina:

• Intravitreal Brimonidine Drug Delivery System (Brimonidine DDS) in Patients with Geographic Atrophy: A Phase 2 Study
  • Date and Time: Friday, October 14, 2016, 4:32 PM-4:37 PM
  • Location: North Building, Hall B
  • Presenter: William R. Freeman, MD

• A Multicenter, Double Masked Phase 2 Clinical Trial Evaluating Abicipar Pegol for Diabetic Macular Edema
  • Date and Time: Saturday, October 15, 2016, 11:27 AM-11:32 AM
  • Location: North Building, Hall B
  • Presenter: Tarek S. Hassan, MD

• Assessing the Association Between Duration of Edema and Visual Acuity Outcomes in Diabetic Macular Edema: A Post-Hoc Analysis of Protocol I
  • Date and Time: Monday, October 17, 2016, 12:30 PM-2:00 PM
  • Location: South Building, Hall A
  • Presenter: Srinivas R. Sadda, MD

Glaucoma:

• Treatment of Newly Diagnosed Open-Angle Glaucoma Patients Over a 4-Year Period: An Analysis of U.S. Claims Data
  • Date and Time: Sunday, October 16, 2016, 12:30 PM-2:00 PM
  • Location: South Building, Hall A
  • Presenter: Gail F. Schwartz, MD

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives everyday.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting future clinical results based on prior clinical results; the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; the ability of Allergan to complete the acquisition of Vitae Pharmaceuticals, Inc.; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:

Investors:
Lisa DeFrancesco
(862) 261-7152

Media: 
Mark Marmur
(973) 906-1526

SOURCE Allergan plc

Related Links

http://www.allergan.com